Company: Dr. Reddy's Laboratories Ltd. Category: IPO Notes

Dr. Reddy’s Laboratories or DRL’s revenues in 3QFY19 at Rs 38,500mn were in line with our estimate as well as consensus estimate. However, net earnings at Rs4,878mn were 10%/29% above our estimate/consensus estimate, respectively.
Feb. 4, 2019, 11:34 a.m.

DRL’s revenues increased by 7% YoY to Rs 37.9 bn (lower than our estimates of Rs 38.9 bn) primarily due to de-growth in US business on account of higher pricing pressure due to incremental competition in some of the key products.
Oct. 29, 2018, 11:38 a.m.

Dr. Reddy’s Laboratories or DRL’s 2QFY19 earnings at Rs5,038mn were 35%/45% above our/consensus estimates, respectively, and up 10.5% QoQ.
Oct. 29, 2018, 11:29 a.m.

DRRD’s sales are in line with our estimates while EBITDA missed by 8% due to higher contribution of low margin sales from emerging markets.
Oct. 26, 2018, 11:47 a.m.

Dr. Reddy’s Laboratories or DRL reported a strong performance in 1QFY19 as its revenues (Rs37,207mn) grew 5.3% QoQ and 12.2% YoY, which were driven by growth across businesses and geographies. Revenues were above our/consensus estimates by 4.6%/ 6.2%, respectively.
July 27, 2018, 1:20 p.m.

We have presented here a review of the key events that impacted Dr. Reddy’s Laboratories or DRL’s performance in FY18 and its outlook for FY19 based on a close reading of its annual report for 2017-18 and 20F filing.
July 23, 2018, 11:07 a.m.

DRRD launched gSuboxone sublingual films post approval in all the four dosage strengths from USFDA
June 15, 2018, 3:59 p.m.

Motilal Oswal stays Neutral on Dr Reddy’s Labs
June 15, 2018, 12:23 p.m.

Dr. Reddy’s Laboratories: 4QFY18 Result Update
May 23, 2018, 2:10 p.m.

Dr. Reddy’s Laboratories: 2QFY18 Result Update
Nov. 1, 2017, 11:17 a.m.
Author : Nirmal Bang | Publisher: